Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nat Cancer. 2024 Jun;5(6):844-865. doi: 10.1038/s43018-024-00777-2. Epub 2024 Jun 27.
Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including disease initiation, maintenance and therapy resistance. As a result, there have been advances in the development and evaluation of epigenetic therapies for cancer, revealing substantial promise but also challenges. Three epigenetic inhibitor classes are approved in the USA, and many more are currently undergoing clinical investigation. In this Review, we discuss recent developments for each epigenetic drug class and their implications for therapy, as well as highlight new insights into the role of epigenetics in cancer.
表观遗传失调越来越被认为是癌症的一个标志，包括疾病的起始、维持和治疗抵抗。因此，在开发和评估癌症的表观遗传学治疗方法方面取得了进展，显示出了很大的希望，但也带来了挑战。在美国，有三种表观遗传抑制剂类药物获得批准，还有更多的药物正在进行临床研究。在这篇综述中，我们讨论了每一种表观遗传药物类别的最新进展及其对治疗的意义，并强调了对癌症中表观遗传学作用的新认识。
